OverviewSuggest Edit

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates. The Company's lead product candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic.

TypePublic
Founded2006
HQHouston, US
Websitemoleculin.com

Latest Updates

Employees (est.) (Dec 2018)9(+350%)
Revenue (FY, 2019)$0
Share Price (Sept 2020)$0.8 (+4%)
Cybersecurity ratingAMore

Key People/Management at Moleculin Biotech

Donald Picker

Donald Picker

Chief Science Officer
Walter V. Klemp

Walter V. Klemp

Founder, President, CEO and Chairman
Sandra Silberman

Sandra Silberman

Chief Medical Officer – New Products
Jonathan P. Foster

Jonathan P. Foster

Executive VP & Chief Financial Officer
Show more

Moleculin Biotech Office Locations

Moleculin Biotech has an office in Houston
Houston, US (HQ)
5300 Memorial Dr #950
Show all (1)

Moleculin Biotech Financials and Metrics

Moleculin Biotech Revenue

USD

Net income (Q2, 2020)

(10.1m)

EBIT (Q2, 2020)

(5.0m)

Market capitalization (23-Sept-2020)

50.6m

Closing stock price (23-Sept-2020)

0.8

Cash (30-Jun-2020)

16.7m

EV

34.1m
Moleculin Biotech's current market capitalization is $50.6 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.4m4.1m5.2m6.3m

R&D expense

1.5m4.5m9.7m11.0m

Operating expense total

3.9m8.6m15.0m17.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

305.6k618.0k924.0k848.0k800.0k1.3m1.4m2.6m1.6m1.5m1.7m1.8m1.7m

R&D expense

15.0k104.8k496.7k683.0k515.0k1.1m1.2m5.5m2.9m2.1m2.8m3.2m3.3m

Operating expense total

320.6k723.5k1.4m1.5m1.3m2.4m2.6m8.1m4.5m3.6m4.5m5.0m5.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.0m7.7m7.1m10.7m

Prepaid Expenses

215.1k588.0k2.7m

Current Assets

5.2m8.3m8.0m13.5m

PP&E

23.1k33.0k316.0k
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.9m)(9.8m)(11.9m)(13.2m)

Depreciation and Amortization

6.2k18.0k68.0k199.0k

Accounts Payable

(41.1k)411.0k436.0k907.0k

Cash From Operating Activities

(3.8m)(7.3m)(12.2m)(17.2m)
USDQ1, 2016

Debt/Equity

-0.9 x

Debt/Assets

2.1 x

Financial Leverage

-0.4 x
Show all financial metrics

Moleculin Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Moleculin Biotech Online and Social Media Presence

Embed Graph

Moleculin Biotech News and Updates

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020

HOUSTON, Aug. 12, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended...

Thinking about buying stock in Caesars Entertainment, Moleculin Biotech, Onconova Therapeutics, Capricor Therapeutics, or Diffusion Pharmaceuticals?

NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CZR, MBRX, ONTX, CAPR, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment

Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as a treatment for COVID-19. The lab involved was IIT Research Institute, an affiliate of the Illinois …

Thinking about buying stock in Moleculin Biotech, VBI Vaccines, Rigel Pharmaceuticals, Delta Air Lines, or Vivint Solar?

NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBRX, VBIV, RIGL, DAL, and VSLR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

HOUSTON, May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first quarter...

Thinking about buying stock in Cronos Group Inc., Hasbro Inc., Moleculin Biotech Inc., Regional Health Properties Inc., or Twitter Inc.?

NEW YORK, April 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRON, HAS, MBRX, RHE, and TWTR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

Moleculin Biotech Blogs

Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team

Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery Joins Moleculin's Science Advisory Board HOUSTON, April 22, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutic…

Moleculin Announces Additional Positive Safety Data in EU AML Trial

A Total of 19 Patients Now Have Shown No Signs of Cardiotoxicity HOUSTON, April 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, toda…

Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate

HOUSTON, March 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has been filed covering…

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019

HOUSTON, March 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended December 31, 2019 and …

Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus

Independent research suggests new approach to inhibiting the viral replication capability of a range of viruses, including Coronavirus HOUSTON, March 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a bro…

Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board

To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in China HOUSTON, March 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ…
Show more

Moleculin Biotech Frequently Asked Questions

  • When was Moleculin Biotech founded?

    Moleculin Biotech was founded in 2006.

  • Who are Moleculin Biotech key executives?

    Moleculin Biotech's key executives are Donald Picker, Walter V. Klemp and Sandra Silberman.

  • How many employees does Moleculin Biotech have?

    Moleculin Biotech has 9 employees.

  • Who are Moleculin Biotech competitors?

    Competitors of Moleculin Biotech include Vivace Therapeutics, Nektar Therapeutics and Northwest Biotherapeutics.

  • Where is Moleculin Biotech headquarters?

    Moleculin Biotech headquarters is located at 5300 Memorial Dr #950, Houston.

  • Where are Moleculin Biotech offices?

    Moleculin Biotech has an office in Houston.

  • How many offices does Moleculin Biotech have?

    Moleculin Biotech has 1 office.